These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24032106)

  • 1. The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.
    Nazha A; Bueso-Ramos C; Estey E; Faderl S; O'Brien S; Fernandez MH; Nguyen M; Koller C; Freireich E; Beran M; Pierce S; Keating M; Cortes J; Kantarjian H; Ravandi F
    Front Oncol; 2013; 3():218. PubMed ID: 24032106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
    Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.
    Schlenk RF; Lübbert M; Benner A; Lamparter A; Krauter J; Herr W; Martin H; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Wattad M; Köhne CH; Fiedler W; Bentz M; Wulf G; Held G; Hertenstein B; Salwender H; Gaidzik VI; Schlegelberger B; Weber D; Döhner K; Ganser A; Döhner H;
    Ann Hematol; 2016 Dec; 95(12):1931-1942. PubMed ID: 27696203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.
    Schlenk RF; Döhner K; Kneba M; Götze K; Hartmann F; Del Valle F; Kirchen H; Koller E; Fischer JT; Bullinger L; Habdank M; Späth D; Groner S; Krebs B; Kayser S; Corbacioglu A; Anhalt A; Benner A; Fröhling S; Döhner H;
    Haematologica; 2009 Jan; 94(1):54-60. PubMed ID: 19059939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase-III study of low-dose cytarabine and etoposide + /- all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia.
    Schlenk RF; Weber D; Krzykalla J; Kindler T; Wulf G; Hertenstein B; Salih HR; Südhoff T; Krauter J; Martens U; Wessendorf S; Runde V; Tischler HJ; Bentz M; Koller E; Heuser M; Thol F; Benner A; Ganser A; Döhner K; Döhner H
    Sci Rep; 2023 Sep; 13(1):14809. PubMed ID: 37684299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Japan Adult Leukemia Study Group.
    Kanamaru A; Takemoto Y; Tanimoto M; Murakami H; Asou N; Kobayashi T; Kuriyama K; Ohmoto E; Sakamaki H; Tsubaki K
    Blood; 1995 Mar; 85(5):1202-6. PubMed ID: 7858250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid therapy for newly diagnosed acute promyelocytic leukemia: comparison with intensive chemotherapy. The Japan Adult Leukemia Study Group (JALSG).
    Asou N; Adachi K; Tamura J; Kanamaru A; Kageyama S; Hiraoka A; Omoto E; Sakamaki H; Tsubaki K; Saito K; Ohno R
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S30-5. PubMed ID: 9272131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with
    Forghieri F; Bigliardi S; Quadrelli C; Morselli M; Potenza L; Paolini A; Colaci E; Barozzi P; Zucchini P; Riva G; Vallerini D; Lagreca I; Marasca R; Narni F; Venditti A; Martelli MP; Falini B; Lo Coco F; Amadori S; Luppi M
    Clin Case Rep; 2016 Dec; 4(12):1138-1146. PubMed ID: 27980750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
    Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
    Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia.
    Schlenk RF; Fröhling S; Hartmann F; Fischer JT; Glasmacher A; del Valle F; Grimminger W; Götze K; Waterhouse C; Schoch R; Pralle H; Mergenthaler HG; Hensel M; Koller E; Kirchen H; Preiss J; Salwender H; Biedermann HG; Kremers S; Griesinger F; Benner A; Addamo B; Döhner K; Haas R; Döhner H;
    Leukemia; 2004 Nov; 18(11):1798-803. PubMed ID: 15385923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of assessing cytogenetic and molecular risk factors in acute myeloid leukemia therapy.
    Coles EC; Colita A; Momanu R; Berbec N; Ivanescu AM; Oprea M; Jardan D; Jardan C; Arghir A; Coriu D; Lupu AR
    J Med Life; 2012; 5(Spec Issue):36-43. PubMed ID: 31803284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.
    Belhabri A; Thomas X; Wattel E; Chelghoum Y; Anglaret B; Vekhoff A; Reman O; Dombret H; Dhedin N; Michallet M; Fière D; Archimbaud E
    Hematol J; 2002; 3(1):49-55. PubMed ID: 11960396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
    Martelli MP; Gionfriddo I; Mezzasoma F; Milano F; Pierangeli S; Mulas F; Pacini R; Tabarrini A; Pettirossi V; Rossi R; Vetro C; Brunetti L; Sportoletti P; Tiacci E; Di Raimondo F; Falini B
    Blood; 2015 May; 125(22):3455-65. PubMed ID: 25795919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA.
    Burnett AK; Hills RK; Green C; Jenkinson S; Koo K; Patel Y; Guy C; Gilkes A; Milligan DW; Goldstone AH; Prentice AG; Wheatley K; Linch DC; Gale RE
    Blood; 2010 Feb; 115(5):948-56. PubMed ID: 19965647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
    J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
    Advani SH; Nair R; Bapna A; Gladstone B; Kadam P; Saikia TK; Parekh PM; Gopal R; Nair CN
    Am J Hematol; 1999 Feb; 60(2):87-93. PubMed ID: 9929098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemtuzumab Ozogamicin in
    Schlenk RF; Paschka P; Krzykalla J; Weber D; Kapp-Schwoerer S; Gaidzik VI; Leis C; Fiedler W; Kindler T; Schroeder T; Mayer K; Lübbert M; Wattad M; Götze K; Horst HA; Koller E; Wulf G; Schleicher J; Bentz M; Greil R; Hertenstein B; Krauter J; Martens U; Nachbaur D; Abu Samra M; Girschikofsky M; Basara N; Benner A; Thol F; Heuser M; Ganser A; Döhner K; Döhner H
    J Clin Oncol; 2020 Feb; 38(6):623-632. PubMed ID: 31851556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of the effects and mechanism of all-trans retinoic acid on leukemic cell line U937 cells with NPM1 mutation].
    Qiu SW; Wan YL; Jia YJ; Rao Q; Wang M; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):863-868. PubMed ID: 29166739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.